Eyes On Pricing As Zolgensma Moves Closer To Japan Market
Possible May Launch?
Executive Summary
Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.
You may also be interested in...
Zolgensma Loses Orphan Benefit in Germany After 'Very High Sales'
Zolgensma has exceeded the orphan sales threshold in the six months it has been on the market in Germany and the gene therapy must now undergo a full benefit assessment.
FDA Says GMP Lapses In Facilities And Production Areas More Common For Cell And Gene Therapies
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.
Novartis Close To EU Approval For Zolgensma At Last
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.